1. Home
  2. TGLS vs ADPT Comparison

TGLS vs ADPT Comparison

Compare TGLS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

HOLD

Current Price

$42.13

Market Cap

1.9B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$16.83

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGLS
ADPT
Founded
1984
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.2B
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
TGLS
ADPT
Price
$42.13
$16.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$63.33
$17.78
AVG Volume (30 Days)
305.4K
1.6M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
1.41%
N/A
EPS Growth
N/A
63.89
EPS
0.71
N/A
Revenue
$370,984,000.00
$276,976,000.00
Revenue This Year
$13.56
$3.98
Revenue Next Year
$9.04
$22.72
P/E Ratio
$60.20
N/A
Revenue Growth
17.98
54.77
52 Week Low
$37.52
$9.96
52 Week High
$89.66
$20.76

Technical Indicators

Market Signals
Indicator
TGLS
ADPT
Relative Strength Index (RSI) 48.74 63.49
Support Level $40.35 $16.55
Resistance Level $46.41 $17.52
Average True Range (ATR) 1.62 0.90
MACD 0.24 0.38
Stochastic Oscillator 54.21 72.62

Price Performance

Historical Comparison
TGLS
ADPT

About TGLS Tecnoglass Inc.

Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: